Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.48 |
| ▸ | ITGAV | P06756 | 11/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 6/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.48 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.48 |
| ▸ | MC4R | P32245 | 6/20 | 0.47 |
| ▸ | MC5R | P33032 | 6/20 | 0.47 |
| ▸ | MC3R | P41968 | 6/20 | 0.47 |
| ▸ | MC1R | Q01726 | 6/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17029693 | 0.94 | ITGB3 (0.45) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL13107808 | 0.89 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL12547669 | 0.89 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL16946584 | 0.89 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL14885799 | 0.89 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL12808284 | 0.89 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL19605481 | 0.89 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL7743533 | 0.89 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL21475019 | 0.89 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL7743878 | 0.89 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2182974-B1 | CYCLIC AZAPEPTIDES AS INTEGRIN MARKERS | SIEMENS MEDICAL SOLUTIONS (US) | 2015-08-26 | — | — | EP | disclosed |
| US-8486372-B2 | Cyclic azapeptides as integrin markers and methods of using | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486372-B2 | Cyclic azapeptides as integrin markers and methods of using | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8043601-B2 | Cyclic azapeptides as integrin markers | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8043601-B2 | Cyclic azapeptides as integrin markers | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8043601-B2 | Cyclic azapeptides as integrin markers | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110256057-A1 | Cyclic Azapeptides as Integrin Markers and Methods of Using | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110256057-A1 | Cyclic Azapeptides as Integrin Markers and Methods of Using | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20090074664-A1 | CYCLIC AZAPEPTIDES AS INTEGRIN MARKERS | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090074664-A1 | CYCLIC AZAPEPTIDES AS INTEGRIN MARKERS | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090074664-A1 | CYCLIC AZAPEPTIDES AS INTEGRIN MARKERS | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-03-19 | — | — | US | disclosed |
| WO-2009018175-A2 | CYCLIC AZAPEPTIDES AS INTEGRIN MARKERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110256057-A1 | Cyclic Azapeptides as Integrin Markers and Methods of Using | ITGAV, ITGB3, ITGA2B | ITGB3 2/4885ITGAV 1/4885ITGB5 10/4885 |
| US-20090074664-A1 | CYCLIC AZAPEPTIDES AS INTEGRIN MARKERS | ITGAV, ITGB3, ITGA2B | ITGB3 2/4885ITGAV 1/4885ITGB5 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.